One of the initial steps of formulating a pharmaceutical social media strategy is considering what resources will be required and forming an internal social media team. My original thinking on this topic (which you can find by following the above link) is that an internal social media team should originally start in a “command and control” model and evolve to the more sophisticated hub and spoke model.
When you arrive at the hub and spoke, the ideal scenario is to have all departments involved that have customer touchpoints. That means the patient call center, the sales reps, the marketing team, etc…In social media, it’s important to operate under the assumption that any employee with access to the company ultimately serves as an ambassador to your brand. I think this still holds true. However, there is an important piece missing from the social media team—the patient.
This isn’t a concept that should be foreign to a pharmaceutical company. They routinely work with patient advocates, form support groups and interact with the patient during the clinical trial period. Even in other parts of the business, pharmaceutical companies are accustomed to representing interests other than their own. For example, in alliance management, it is important that a member of the organization is continually looking out for the interest of the alliance partner. That person always has a seat at the table.
Following the same logic, shouldn’t the patient always have a seat at the social media table?
If we buy into the concept that a healthcare company involved in social media should do so with the objective of improving health outcomes and informing better health decisions, than a patient should be involved in the planning process. Sure, we can get some of this information ourselves by conducting our due diligence, listening to social media chatter and evaluating the current needs of patients. But there is no substitute for actually speaking with the patient.
Are there some legal barriers to this approach? Of course. But it’s nothing a legal team couldn’t figure out. The FDA is concerned with how pharmaceutical companies push messages to patients, what better way to improve that process than by bringing them into the fold.
Consider it a focus group for social media.
A common question asked by healthcare marketers before engaging in social media is whether or not their patients are online.
My feeling has always been that pharmaceutical marketers have leaned on the
By now you’ve heard that
Raise your right hand and repeat after me:
Congrats! You’ve decided to embark on a pharmaceutical social media odyssey. It will be a rewarding endeavor. You’ve done everything right up until this point: focused on the 
